Vectibix colon cancer drug

Introduced to the UK earlier this year, Vectibix is currently licensed for patients with metastatic bowel cancer for whom standard chemotherapy has failed in patients with a specific gene mutation.

In a biomarker analysis of the pivotal clinical trial, the drug doubled survival rates in patients with a non-mutated KRAS gene compared with patients receiving best supportive care alone, Lab21 said.

Approximately 60 per cent of patients with advanced bowel cancer have wild type KRAS, and of these, up to 60 per cent would be expected to respond to Vectibix.

read more http://www.businessweekly.co.uk/2008031731605/life-sciences/new-cancer-drug-screening-gets-lab21-salute.html